Abeona Therapeutics Announces First Patient Treated in Pivotal Phase III Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa Mar 17, 2020
Abeona Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Business Updates Mar 16, 2020
Abeona Therapeutics to Present at the 9th Annual SVB Leerink Global Healthcare Conference Feb 26, 2020
Abeona Therapeutics Announces Positive Interim Data from MPS III Gene Therapy Programs Presented at WORLDSymposium™ Feb 12, 2020
Abeona Therapeutics Announces Participation in Inaugural World Congress on Epidermolysis Bullosa Jan 21, 2020
Abeona Therapeutics Initiates Pivotal Phase 3 Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa Jan 13, 2020
Abeona Announces Closing of $103.5 Million Underwritten Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares Dec 24, 2019
Abeona Therapeutics Receives European Medicines Agency PRIME Designation for ABO-102 Gene Therapy in MPS IIIA Dec 20, 2019
